Fund of the week: Should you follow Woodford?
Neil Woodford is arguably Britain's most successful working fund manager. And for investors, his fund holds a few surprises.
Star fund manager Neil Woodford hasrevealed all 61 stocks in his new CFWoodford Equity Income Fund. Manyare long-term Woodford favourites, butthere are a few surprises too (you can seethe full top ten below).
The fund issimilar to the two income funds Woodfordran at Invesco Perpetual. As before, he isinvesting heavily in pharmaceutical andtobacco stocks. He likes these becausethey deliver reliable, growing cash flows.
The one surprise in the top ten' is Imperial Innovations, which commercialises technologies developed at British universitylabs. Many income funds wouldn't invest in a company likethis, as it pays no dividend. But it's clearly a favourite theme ofWoodford's outside the top ten, he has invested in several othertechnology stocks. In 11th place you'll find Allied Minds (LSE:ALM), which commercialises innovations from US universities.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
There are several biotechs too, including E-Therapeutics (LSE:ETX), Vernalis (LSE: VER) and Reneuron (LSE: RENE). None paysa dividend. Yet Woodford still expects the fund to pay a 4% yield.Should you invest?
Woodford has an outstanding long-termrecord. If you had put £1,000 in his Invesco Perpetual HighIncome Fund in 1988, it would have been worth just under£25,000 when he gave up the fund earlier this year.
He's arguablythe most successful working fund manager in the UK. But inrecent years, his performance hasn't been so strong. Accordingto Citywire, he's the 19th best-performing equity incomemanager over the last three years, of a field of 73 decent, butnot amazing. And the man who has taken over Woodford's oldfunds at Invesco Perpetual, Mark Barnett, comes fifth in that list.
Charges are pretty much as you'd expect on most investmentplatforms, you'll pay a 0.75% annual management charge,although it's 0.6% via Hargreaves Lansdown.
But if your priorityis low charges, you would do better with the Vanguard FTSE UKEquity Income Index Fund. This passive fund, which tracks anequity income index, has an annual charge of just 0.25%.
AstraZeneca (LSE: AZN) | Pharmaceuticals | 8.3 |
GlaxoSmithKline (LSE: GSK) | Pharmaceuticals | 7.1 |
British American Tob'cco (LSE: BATS) | Tobacco | 6.2 |
BT (LSE: BT) | Telecoms | 6 |
Imperial Tobacco (LSE: IMT) | Tobacco | 5.3 |
Roche (SIX: ROG) | Pharmaceuticals | 3.9 |
Imperial Innovations (LSE: IVO) | Financials | 3.6 |
Reynolds American (NYSE: RAI) | Tobacco | 3.6 |
Rolls-Royce (LSE: RR) | Aerospace/engineering | 3.5 |
Capita (LSE: CPI) | Outsourcing | 3.4 |
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Why CEOs deserve a pay rise
Opinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
By Stuart Watkins Published
-
Europe prepares to stand alone as Trump turns on Ukraine
Support for old military alliances is wavering in the US under Donald Trump. Europe’s leaders are rushing to fill the void. Simon Wilson reports
By Simon Wilson Published